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Previewspeptidases whose expression is strongly
IMD dependent, is severely impaired.
Accordingly, Lactobacillus-induced intes-
tinal proteolytic activity was almost
completely abolished following enteric
infection, thereby antagonizing the
Lactobacillus-induced growth-promoting
effect. Although enteric infection antago-
nizes Lactobacillus-induced growth pro-
motion, it does not alter the growth of
GF animals. These data indicate that
enteric infection specifically antagonizes
Lactobacillus-induced signaling path-
ways (see step 2 and 11 in Figure 1). As
gut-specific overexpression of a single
Jon66Cii peptidase is sufficient to sup-
press the growth-antagonizing effect
of Ecc15, the authors concluded that
Ecc15 pathogen infection inhibits Lacto-
bacillus-mediated growth promotion by
negatively regulating the expression of in-
testinal peptidase genes.
As this antagonizing effect can also be
observed in an IMD pathway mutant an-
imal, IMD pathway activation is dispens-
able for infection-induced antagonism.
However, when they performed an infec-
tion with avirulent Ecc15 strain lacking
the erwinia virulence factor (evf) gene
(Basset et al., 2003), the authors found
that Lactobacillus-induced growth pro-
motion was not affected. Therefore,390 Cell Host & Microbe 18, October 14, 201enteric infection may induce a signaling
pathway in an evf-specific manner that
in turn antagonizes strain-specific Lacto-
bacillus signaling (see step 2 and 11
in Figure 1). This growth-antagonizing
effect of Ecc15 would act as a physio-
logical switch shifting the expression
of digestive genes involved in meta-
bolism and development to the expres-
sion of innate immune effector genes
involved in pathogen resistance and tis-
sue repair.
These discoveries raise several inter-
esting questions for future research
directions. What is the Lactobacillus-
induced signaling pathway involved in
the induction of peptidase expression?
How does this signaling pathway operate
in a Lactobacillus strain-specific manner?
What is the Ecc15-induced signaling
pathway capable of antagonizing Lacto-
bacillus-induced host growth? What is
the molecular mechanism by which
the evf-specific signaling inhibits the
Lactobacillus strain-specific signaling
pathway? What is the in vivo value of
this physiological switch? Further investi-
gations will provide mechanistic insights
into the probiotic functions of Lactobacilli
in Drosophila and, hopefully, in more
complex mammalian organisms, includ-
ing humans.5 ª2015 Elsevier Inc.ACKNOWLEDGMENTS
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Virulent group A streptococci have become a serious threat, with the emergence of the hypervirulent lineage
M1T1. In this issue of Cell Host & Microbe, LaRock et al. (2015), uncover a role for the streptococcal M1 pro-
tein in neutralizing a key human antimicrobial peptide, cathelicidin.Since the mid-1980s, group A strepto-
cocci (GAS) have reemerged as a cause
of severe invasive infections, such as sep-
tic shock, puerperal sepsis, soft-tissue in-
fections including necrotizing fasciitis,
and streptococcal toxic shock syndrome.
Despite increased awareness and bettertreatment of the most severe disease
manifestations, the mortality rate remains
high, often exceeding 50%. To date, more
than 150 different M protein sequence
types (emm types) have been described
for GAS. Although the most severe forms
of invasive GAS infections, streptococcaltoxic shock syndrome and necrotizing
fasciitis, can be caused by a large number
of emm types, they are particularly asso-
ciated with emm1 (M1). One example
of the rapid progress of M1 infections
was recently reported for three cases
of fulminant hemorrhagic pneumonia in
Cell Host & Microbe
Previewspreviously healthy patients (Santagati
et al., 2014). These patients developed
hemoptysis and dyspnea, and all three
died within 12 hr from massive pulmonary
bleeding. Postmortem analysis showed
that the illnesses were caused by emm1
strains. This clinical picture suggests a
pathogen that is highly toxic and tissue
damaging and resistant to early innate
clearing systems, thus allowing unre-
stricted growth.
This epidemic clone emerged in a
step-wise manner from a less virulent
M1 ancestor culminating in the 1980s
by acquisition of a large chromosomal
region encoding the secreted toxins
NADase and streptolysin O (Nasser
et al., 2014). This genetic event has been
suggested to act as the key driver for
increased toxin production and enhanced
infection severity of current M1 pandemic
strains.
The M1 surface protein is not just a
marker for this successful and highly viru-
lent lineage. The protein itself has been
shown to contribute to the intracellular
survival of S. pyogenes in macrophages
(Hertze´n et al., 2010), and recently it was
demonstrated that the M1 protein triggers
chemokine formation, neutrophil infiltra-
tion, and lung injury in a process depen-
dent upon the transcriptional factor
NFAT (Zhang et al., 2015).
In this issue, LaRock et al. (2015)
demonstrate that the M1 protein has yet
another function—namely to mediate
resistance of emm1 strains to the human
cathelicidin LL-37, aswell as to themouse
equivalent, CRAMP. It has been shown
previously that emm1 strains are consid-
erably more resistant to cathelicidins
than GAS strains of other emm types
(Lauth et al., 2009). LL-37 is the only
known human cathelicidin. Like the de-
fensins, cathelicidins act as natural anti-
microbials, but also have a number of
other functions in the regulation of im-
mune cell activation and their migration,
and in modulating many physiological
processes that involve non-immune cells,
such as activation of wound healing,angiogenesis, and cartilage remodeling.
LL-37 has also been suggested to play a
role in the pathogenesis of psoriasis by
acting as a T cell auto-antigen (Lande
et al., 2014). Cathelicidins are primarily
formed in neutrophils, but can also be
produced by macrophages, mast cells,
and keratinocytes. They are released as
a pro-form that needs to be processed
to generate biologically active peptide.
Here, LaRock et al. (2105) demonstrate
that emm1 strains sequester the pro-
form of LL-37, as well as LL-37 itself, via
a region on M1 localized close to the cell
membrane. LL-37, binding to the M1 pro-
tein, appears specific as no binding was
observed with defensins. Binding of pro-
LL-37 is usually followed by its proteolytic
cleavage, but this did not occur when
sequestered by the M1 protein. This ex-
plains why emm1 strains become pro-
tected from the direct killing action of
LL-37, but also from the innate activation
functions of LL-37, such as stimulation
of immune cell migration. Using a local-
ized skin wound model, it was demon-
strated that M1 strains give rise to similar
sized lesions in wild-type and CRAMP/
mice, suggesting that M1 expression pro-
tects against the local innate immune
effects of cathelicidins.
There have been earlier reports
showing that proteases expressed by a
number of bacterial pathogens including
GAS can degrade and inactivate antimi-
crobial peptides such as LL-37. GAS
strains have been shown to secrete the
SIC protease, and it was demonstrated
that SIC fromM1 strains was more potent
in degrading LL-37 than other GAS strains
(Frick et al., 2003). GAS strains can also
express GRAB, a surface associated pro-
tein that sequesters alpha(2)-macroglob-
ulin, which is a major proteinase inhibitor
of human plasma. Trapping of alpha(2)-
macroglobulin by GRAB allows GAS to
retain the normally secreted SpeB prote-
ase on its surface, which in turn can pro-
tect against killing by LL-37 (Nyberg
et al., 2004). Finally, it has been demon-
strated using M1 strains that LL-37 canCell Host & Microbe 18directly bind to the histidine kinase sensor
CsrS in the two-component system
CsrRS, resulting in upregulation of a num-
ber of virulence-associated GAS genes
(Velarde et al., 2014). It would be inter-
esting to know if the sequestering of LL-
37 by M1 contributes to this upregulation
of GAS virulence. A detailed study on the
exact mechanism for pro-LL-37 and
LL-37 binding to M1 might give further
insights into the intimate relationship
between the emerging global pathogen
GAS of emm1, and one of the early innate
immune defense molecules, LL-37.REFERENCES
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